Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Teclistamab Demonstrates Exciting Efficacy in Relapsed or Refractory Multiple Myeloma

February 9th 2023

Alfred L. Garfall, MD, discusses the durability of responses teclistamab elicited in the MajesTEC-1 trial and how this agent will change the treatment regimen for relapsed/refractory multiple myeloma.

Dr. Fallon on Supportive Care Considerations in R/R Multiple Myeloma

February 8th 2023

Michael J. Fallon, MD, discusses supportive care considerations for patients with relapsed/refractory multiple myeloma.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Exploring Key Takeaways from the DETERMINATION Trial

February 8th 2023

In this fifth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, reviews the implications of up-front vs delayed transplant on survival, quality of life, and risk of secondary malignancies in newly diagnosed, multiple myeloma.

Dr. Carlo-Stella on the Investigation of RG6234 in R/R Multiple Myeloma

February 7th 2023

Carmelo Carlo-Stella, MD, PhD, discusses the evaluation of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Dr. Siegel on the Importance of Investigating Ide-cel in Multiple Myeloma

February 7th 2023

David Siegel, MD, PhD, discusses the importance of investigating idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Patient Assessment Drives Treatment Advances in Multiple Myeloma

February 6th 2023

Natalie S. Callander, MD, contextualizes the implications of the phase 3 ATLAS trial findings alongside other trials investigating maintenance regimens with triplet therapies in multiple myeloma.

Quadruplet Combination Therapies in Relapsed Multiple Myeloma

February 6th 2023

Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.

Strategies for Treatment of Multiple Myeloma at Late Relapse

February 6th 2023

The panel debates the options for treatment of late relapsed multiple myeloma.

Post-Transplant KRd Maintenance May Allow for Superior Outcomes in Newly Diagnosed Multiple Myeloma

February 3rd 2023

Andrzej Jakubowiak, MD, PhD, highlighted several key studies that influenced the development and design of the ATLAS trial, introduced conclusions from the initial efficacy data, and discussed how ongoing analysis could further contextualize and inform post-transplant treatment approaches in multiple myeloma.

Dr. Siegel on Updated Results From the KarMMA-2 Trial in R/R Multiple Myeloma

February 2nd 2023

David Siegel, MD, discusses the significance of updated data from cohort 2C of the phase 2 KarMMa-2 trial in multiple myeloma.

Dr. Searle on Initial Results From the MajesTEC-2 Trial in Multiple Myeloma

February 2nd 2023

Emma Searle, MD, discusses early findings from cohort E of the phase 1b MajesTEC-2 trial (NCT04722146) evaluating teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in multiple myeloma.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Taking a Closer Look at Cilta-cel and CARTITUDE-1 Data

February 1st 2023

In this fourth episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, explains the optimal use of CAR T-cell therapy and common symptoms of adverse effects, including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome in relapsed/refractory multiple myeloma.

Dr. Jakubowiak on Initial Efficacy Data From the ATLAS Trial in Multiple Myeloma

January 30th 2023

Andrzej Jakubowiak, MD, PhD, discusses initial efficacy results from the phase 3 ATLAS trial in multiple myeloma.

Data Updates in the Treatment of Relapsed Multiple Myeloma

January 30th 2023

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Relapse in Multiple Myeloma: Biochemical and Chemical

January 30th 2023

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Shaji Kumar, MD, discusses the MAIA trial; key takeaways regarding the long-term safety and efficacy of daratumumab, lenalidomide, and dexamethasone, in transplant-ineligible patients with newly diagnosed multiple myeloma; and the implications of this research on clinical practice.

Cilta-cel Meets PFS End Point in Relapsed/Lenalidomide-Refractory Multiple Myeloma

January 27th 2023

Ciltacabtagene autoleucel demonstrated a significant improvement in progression-free survival in patients with relapsed/lenalidomide-refractory multiple myeloma who received 1 to 3 prior lines of therapy.

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Maintenance therapy with carfilzomib, lenalidomide, and dexamethasone led to a significant improvement in progression-free survival vs lenalidomide alone in patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant after induction therapy, according to an unplanned interim analysis of the phase 3 ATLAS trial.

Unpacking Data From Pivotal Trials in Multiple Myeloma: Lessons Learned From the MajesTEC-1 Trial of Teclistamab

January 25th 2023

In this third episode of OncChats: Unpacking Data From Pivotal Trials in Multiple Myeloma, Hamza Hashmi, MD, highlights the efficacy and safety profile of teclistamab, a BCMA-directed bispecific T-cell engager, in heavily pretreated multiple myeloma.

Dr. Giralt on Long-Term Outcomes with HSCT in Multiple Myeloma

January 25th 2023

Sergio A. Giralt, MD, discusses long-term outcomes with hematopoietic stem cell transplant in multiple myeloma